PITPNM3 and cancer: After binding, PITPNM3 will phosphorylate PTK2B via PTK2B binding domain which leads to metastasis‐related signaling pathways activation.[3, 7, 9] This process promotes cancer metastasis, on the other hand, transforms cancer cells into mesenchymal phenotype.